IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

Thank you for standing by and welcome to the Axonics' First Quarter 2023 Results Conference Call. At this time, all participants are in listen-only mode. After the speakers' presentation, there will ...

Barely 6 months after raising a $38.5 million Series B to advance its neuromodulation implant to treat overactive bladder and fecal dysfunction, Axonics Modulation Technologies won a CE mark for the ...

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral ...

IRVINE, Calif. - Axonics, Inc. (NASDAQ: AXNX), a medical technology firm specializing in bladder and bowel dysfunction treatments, has announced the receipt of CE Mark approval for its Axonics R20™ ...

US Medical device giant Axonics has announced that it has secured market clearance from Australia’s Therapeutic Goods Administration (TGA) for its R20 rechargeable sacral neuromodulation (SNM) system ...

Irvine-based Axonics Modulation Technologies Inc. (Nasdaq: AXNX) has been granted Food and Drug Administration approval for its device for overactive bladders. The rechargeable implantable ...

OWINGS MILLS, Md., Aug. 21, 2020 /PRNewswire/ -- Three Chesapeake Urology physicians and their teams have been designated as Axonics Centers of Excellence by Axonics Modulation Technologies, Inc. The ...

Ladies and gentlemen, thank you for standing by. Welcome to the Axonics Third Quarter 2023 Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.